Tilray Brands Stock Rises After Upgrade Following Q3 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy TLRY?
Source: seekingalpha
- International Business Growth: Tilray's international segment saw approximately 73% year-over-year growth in Q3 FY26, contributing over a third of the company's total revenue, indicating strong performance in global markets that is expected to drive overall company results further.
- Capacity Enhancement Potential: Analyst William Kirk noted that Tilray's international business is at an inflection point, with plans to increase capacity from the current 137 metric tons to around 200 metric tons, which will significantly enhance the company's competitive position and profitability.
- Canadian Market Stability: As supply shifts to international markets, Tilray's core Canadian business is experiencing significantly less price pressure, maintaining its market share leadership, indicating that the company's robust domestic performance lays a solid foundation for future growth.
- Optimistic Outlook: Kirk maintains a $10 price target for Tilray, believing that the stock's recovery since July 2025, along with management's strategy to slow down share issuance, has bolstered market confidence in its future, especially against a backdrop of potential regulatory improvements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 6.140
Low
8.50
Averages
9.57
High
10.00
Current: 6.140
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. It operates through four segments: cannabis operations, beverage operations, distribution operations, and the wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The beverage operations, which encompasses the production, marketing and of beverage products. The distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers. The Wellness products, which encompasses wellness and better-for-you foods and beverages. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, Chowie Wowie and others. It supports over 40 brands in over 20 countries, including cannabis offerings, hemp-based foods and craft beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Brands Stock Rises After Upgrade Following Q3 Earnings
- International Business Growth: Tilray's international segment saw approximately 73% year-over-year growth in Q3 FY26, contributing over a third of the company's total revenue, indicating strong performance in global markets that is expected to drive overall company results further.
- Capacity Enhancement Potential: Analyst William Kirk noted that Tilray's international business is at an inflection point, with plans to increase capacity from the current 137 metric tons to around 200 metric tons, which will significantly enhance the company's competitive position and profitability.
- Canadian Market Stability: As supply shifts to international markets, Tilray's core Canadian business is experiencing significantly less price pressure, maintaining its market share leadership, indicating that the company's robust domestic performance lays a solid foundation for future growth.
- Optimistic Outlook: Kirk maintains a $10 price target for Tilray, believing that the stock's recovery since July 2025, along with management's strategy to slow down share issuance, has bolstered market confidence in its future, especially against a backdrop of potential regulatory improvements.
See More
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
Tilray's Q3 Results Mixed Amid Regulatory Concerns
- Rating Upgrade: Roth Capital upgraded Tilray's rating from 'Neutral' to 'Overweight' while maintaining a $10 price target, indicating confidence in the company's international growth despite regulatory uncertainties looming over the industry.
- Earnings Highlights: Tilray reported a 19% year-over-year revenue increase to $206.7 million, surpassing the $201.3 million expectation, while net loss significantly narrowed to $25.2 million, reflecting improvements in business fundamentals.
- Market Reaction: Despite the positive earnings report, TLRY shares fell 1.5% in early Thursday trading, highlighting investor concerns regarding increasing regulatory restrictions on cannabis products in the U.S.
- Analyst Sentiment: While Alliance Global lowered its price target on TLRY to $7, the overall analyst outlook remains cautious, with 7 out of 10 analysts rating the stock as 'Hold', indicating a divergence in views on future growth potential.
See More
Tilray Brands Reports Record Q3 Revenue Driven by International Growth and Strategic Acquisitions
- Record Revenue: Tilray achieved net revenue of $206.7 million in Q3 FY2026, reflecting strong growth in international markets, which is expected to drive further growth in the future.
- International Market Growth: International cannabis sales reached $24.1 million, marking a 73% year-over-year increase, indicating Tilray's successful global positioning, particularly with its distribution network expanding to over 16,000 pharmacies in Germany, enhancing market penetration.
- Strategic Acquisitions and Partnerships: Tilray acquired BrewDog for approximately EUR 40 million, expected to elevate its global craft beverage platform to around $500 million, while also entering a strategic licensing partnership with Carlsberg set to launch in January 2027, further strengthening its beverage business.
- Profitability and Outlook: The company reaffirmed its fiscal 2026 adjusted EBITDA guidance range of $62 million to $72 million, and despite facing price pressures and rising aluminum costs, management remains optimistic about future profitability.
See More
Tilray Brands Reports Record Q3 Revenue of $206.7 Million
- Significant Revenue Growth: Tilray Brands Inc (NASDAQ:TLRY) achieved a record third-quarter revenue of $206.7 million, marking an 11% year-over-year increase, demonstrating strong performance in international markets, particularly with a 73% rise in international cannabis revenue and a 43% growth in Germany, laying a solid foundation for future expansion.
- Cost Savings Impact: The successful completion of Project 420 resulted in $33 million in annualized cost savings, improving the underlying cost structure of the beverage business, which enhances the company's profitability in a highly competitive market.
- Strategic Acquisition Boost: The acquisition of BrewDog positions Tilray as a $1.2 billion global revenue company, significantly enhancing its long-term growth profile, indicating its commitment to expanding in the global beverage market.
- Strong Financial Position: Tilray maintains a robust financial position with $265 million in cash, restricted cash, and marketable securities, providing flexibility for future growth investments, despite facing integration and regulatory challenges in international markets.
See More
Tilray Brands Stock Rises After Upgrade Following Q3 Earnings
- International Business Growth: Tilray's international segment saw approximately 73% year-over-year growth in Q3 FY26, contributing over a third of the company's total revenue, indicating strong performance in global markets that is expected to drive overall company results further.
- Capacity Enhancement Potential: Analyst William Kirk noted that Tilray's international business is at an inflection point, with plans to increase capacity from the current 137 metric tons to around 200 metric tons, which will significantly enhance the company's competitive position and profitability.
- Canadian Market Stability: As supply shifts to international markets, Tilray's core Canadian business is experiencing significantly less price pressure, maintaining its market share leadership, indicating that the company's robust domestic performance lays a solid foundation for future growth.
- Optimistic Outlook: Kirk maintains a $10 price target for Tilray, believing that the stock's recovery since July 2025, along with management's strategy to slow down share issuance, has bolstered market confidence in its future, especially against a backdrop of potential regulatory improvements.
See More
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
Tilray's Q3 Results Mixed Amid Regulatory Concerns
- Rating Upgrade: Roth Capital upgraded Tilray's rating from 'Neutral' to 'Overweight' while maintaining a $10 price target, indicating confidence in the company's international growth despite regulatory uncertainties looming over the industry.
- Earnings Highlights: Tilray reported a 19% year-over-year revenue increase to $206.7 million, surpassing the $201.3 million expectation, while net loss significantly narrowed to $25.2 million, reflecting improvements in business fundamentals.
- Market Reaction: Despite the positive earnings report, TLRY shares fell 1.5% in early Thursday trading, highlighting investor concerns regarding increasing regulatory restrictions on cannabis products in the U.S.
- Analyst Sentiment: While Alliance Global lowered its price target on TLRY to $7, the overall analyst outlook remains cautious, with 7 out of 10 analysts rating the stock as 'Hold', indicating a divergence in views on future growth potential.
See More
Tilray Brands Reports Record Q3 Revenue Driven by International Growth and Strategic Acquisitions
- Record Revenue: Tilray achieved net revenue of $206.7 million in Q3 FY2026, reflecting strong growth in international markets, which is expected to drive further growth in the future.
- International Market Growth: International cannabis sales reached $24.1 million, marking a 73% year-over-year increase, indicating Tilray's successful global positioning, particularly with its distribution network expanding to over 16,000 pharmacies in Germany, enhancing market penetration.
- Strategic Acquisitions and Partnerships: Tilray acquired BrewDog for approximately EUR 40 million, expected to elevate its global craft beverage platform to around $500 million, while also entering a strategic licensing partnership with Carlsberg set to launch in January 2027, further strengthening its beverage business.
- Profitability and Outlook: The company reaffirmed its fiscal 2026 adjusted EBITDA guidance range of $62 million to $72 million, and despite facing price pressures and rising aluminum costs, management remains optimistic about future profitability.
See More
Tilray Brands Reports Record Q3 Revenue of $206.7 Million
- Significant Revenue Growth: Tilray Brands Inc (NASDAQ:TLRY) achieved a record third-quarter revenue of $206.7 million, marking an 11% year-over-year increase, demonstrating strong performance in international markets, particularly with a 73% rise in international cannabis revenue and a 43% growth in Germany, laying a solid foundation for future expansion.
- Cost Savings Impact: The successful completion of Project 420 resulted in $33 million in annualized cost savings, improving the underlying cost structure of the beverage business, which enhances the company's profitability in a highly competitive market.
- Strategic Acquisition Boost: The acquisition of BrewDog positions Tilray as a $1.2 billion global revenue company, significantly enhancing its long-term growth profile, indicating its commitment to expanding in the global beverage market.
- Strong Financial Position: Tilray maintains a robust financial position with $265 million in cash, restricted cash, and marketable securities, providing flexibility for future growth investments, despite facing integration and regulatory challenges in international markets.
See More
